Product Number : MC537832
CAS Number : 2016-88-8
Molecular Formula : C6H11Cl2N7O2 | Molecular Weight : 284.10
Synonyms : MK-870 hydrochloride
Quote RequestPurity | NLT 98% |
---|---|
Storage | at 20ºC 2 years |
MolCore specializes in manufacturing high-purity CAS No.2016-88-8, Amiloride (hydrochloride) with the molecular formula C6H11Cl2N7O2 and molecular weight 284.10 delivering critical API intermediates for global pharmaceutical and research industries, certified under ISO quality systems. |
* The above information is for reference only.
Chemical Name | Amiloride (hydrochloride) |
---|---|
CAS Number | 2016-88-8 |
MDL Number | MFCD03703482 |
Molecular Formula | C6H11Cl2N7O2 |
Molecular Weight | 284.10 |
Synonyms | MK-870 hydrochloride |
Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC[1]) and urokinase-type plasminogen activator receptor (uTPA[2]). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2[3]) channel. IC50 & Target: ENaC[1]; uTPA[2]; polycystin-2(TRPP2)[3] In Vitro: Amiloride blocks δβγ channels with an IC50 of 2.6 μM. The Ki of amiloride for δβγ ENaC is 26-fold that of αβγ channels (0.1 μM for αβγ ENaC). Amiloride blockade of δβγ ENaC is much more voltage dependent compared with the αβγ channel. The Ki of amiloride for δαβγ channels is 920 and 13.7 μM at −120 and +80 mV, respectively, which significantly differs from that of both αβγ and δβγ channels[1]. Amiloride is a relatively selective inhibitor of the epithelial sodium channel (ENaC) with an IC50 (the concentration required to reach 50% inhibition of an ion channel) in the concentration range of 0.1 to 0.5 μM. Amiloride is a relatively poor inhibitor of the the Na+/H+ exchanger (NHE) with an IC50 as low as 3 μM in the presence of a low external [Na+] but as high as 1 mM in the presence of a high [Na+]. Amiloride is an even weaker inhibitor of the Na+/Ca2+ exchanger (NCX), with an IC50 of 1 mM. Amiloride (1 μM) and submicromolar doses of Benzamil (30 nM), doses known to inhibit the ENaC, inhibit the myogenic vasoconstriction response to increasing perfusion pressure by blocking the activity of ENaC proteins. Amiloride completely inhibits Na+ influx in doses known to be relatively specific for ENaC (1.5 μM) in vascular smooth muscle cells (VSMC)[2]. In Vivo: Amiloride (1 mg/kg/day) subcutaneously is found to reverse the initial increases in collagen deposition and prevent any further increases in the DOCA-salt hypertensive rat. Amiloride delays the onset of proteinuria and improved brain and kidney histologic scores in the saline-drinking, stroke-prone spontaneously hypertensive rats (SHRSP) compared with controls. Amiloride antagonizes or prevents actions of aldosterone in these cells and in cardiovascular and renal tissues in animals with salt-dependent forms of hypertension[2].
© Copyright 2015-2025 Hangzhou MolCore BioPharmatech Co.,Ltd. All rights reserved.